Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 978 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glucophage Clear all
Completed Not applicable Interventional

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

NCT03893422
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
WB-010, WB-011, Placebo
Other
Lead sponsor
Pendulum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Torrance, California • Tustin, California • Youngstown, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

NCT00727857
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and metformin, Pioglitazone, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
38
States / cities
Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

NCT01885260
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

NCT01981525
View directory record Official record
Conditions
Li-Fraumeni Syndrome
Interventions
Metformin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

NCT03826602
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Tucatinib, Metformin, Iohexol
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 17, 2026, 12:59 AM EDT
Withdrawn Phase 4 Interventional

Cardiovascular Effects of Metformin on Obesity

NCT01910246
View directory record Official record
Conditions
Insulin Resistance
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 17, 2026, 12:59 AM EDT
Terminated Phase 2 Interventional

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

NCT05297045
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RGT001-075, Placebo
Drug · Other
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diabetes Risk Education and Communication Trial

NCT03283657
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Body Weight, Body Weight Changes
Interventions
DiRECT, Usual care (UC)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 17, 2026, 12:59 AM EDT
Withdrawn Phase 2 Interventional

Metformin and Vascular Function in Prediabetes

NCT06526494
View directory record Official record
Conditions
PreDiabetes
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Diana Jalal
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

NCT03655301
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Copanlisib (Aliqopa, BAY80-6946), Metformin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents

NCT03981861
View directory record Official record
Conditions
PCOS
Interventions
Metformin and Spironolactone
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 17, 2026, 12:59 AM EDT
Completed No phase listed Observational

Immunometabolism in Pediatric Obesity

NCT03960333
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
5 Years to 17 Years
Enrollment
82 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

NCT03351478
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Empagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Sheffield, Alabama • Hawaiian Gardens, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

NCT00960076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Jonesboro, Arkansas • Anaheim, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 2 Interventional

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

NCT00290940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CS-917, metformin hydrochloride, pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

NCT01128621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 1 Interventional

Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo

NCT02682121
View directory record Official record
Conditions
Prediabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 17, 2026, 12:59 AM EDT
Terminated Phase 1 Interventional

Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes

NCT00332085
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Chromium Picolinate
Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Kenmore, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metformin and Furosemide Drug-Drug Interaction Study

NCT02028689
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg, Metformin 850 mg, Furosemide 40 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 17, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

NCT00082381
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide (AC2993), Insulin glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
21
States / cities
San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 17, 2026, 12:59 AM EDT